Logo image of ADXN

ADDEX THERAPEUTICS LTD (ADXN) Stock Fundamental Analysis

NASDAQ:ADXN - Nasdaq - US00654J2069 - ADR - Currency: USD

7.52  -0.28 (-3.59%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ADXN. ADXN was compared to 572 industry peers in the Biotechnology industry. ADXN has a bad profitability rating. Also its financial health evaluation is rather negative. ADXN has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year ADXN was profitable.
In the past year ADXN has reported a negative cash flow from operations.
In the past 5 years ADXN always reported negative net income.
In the past 5 years ADXN always reported negative operating cash flow.
ADXN Yearly Net Income VS EBIT VS OCF VS FCFADXN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5M -10M -15M -20M

1.2 Ratios

ADXN has a better Return On Assets (44.42%) than 99.64% of its industry peers.
ADXN's Return On Equity of 48.86% is amongst the best of the industry. ADXN outperforms 99.29% of its industry peers.
Industry RankSector Rank
ROA 44.42%
ROE 48.86%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADXN Yearly ROA, ROE, ROICADXN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -500 -1K

1.3 Margins

ADXN's Profit Margin of 912.38% is amongst the best of the industry. ADXN outperforms 99.64% of its industry peers.
The Operating Margin and Gross Margin are not available for ADXN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 912.38%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADXN Yearly Profit, Operating, Gross MarginsADXN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -500 -1K

More info and screens

3

2. Health

2.1 Basic Checks

ADXN does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for ADXN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ADXN Yearly Shares OutstandingADXN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 100K 200K 300K 400K
ADXN Yearly Total Debt VS Total AssetsADXN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M

2.2 Solvency

ADXN has an Altman-Z score of -34.09. This is a bad value and indicates that ADXN is not financially healthy and even has some risk of bankruptcy.
ADXN has a Altman-Z score of -34.09. This is amonst the worse of the industry: ADXN underperforms 92.18% of its industry peers.
ADXN has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
ADXN has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -34.09
ROIC/WACCN/A
WACC4.96%
ADXN Yearly LT Debt VS Equity VS FCFADXN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 4.59 indicates that ADXN has no problem at all paying its short term obligations.
ADXN has a Current ratio (4.59) which is in line with its industry peers.
ADXN has a Quick Ratio of 4.59. This indicates that ADXN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ADXN (4.59) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.59
Quick Ratio 4.59
ADXN Yearly Current Assets VS Current LiabilitesADXN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 119.90% over the past year.
Looking at the last year, ADXN shows a very negative growth in Revenue. The Revenue has decreased by -76.09% in the last year.
ADXN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -24.47% yearly.
EPS 1Y (TTM)119.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.12%
Revenue 1Y (TTM)-76.09%
Revenue growth 3Y-24.84%
Revenue growth 5Y-24.47%
Sales Q2Q%-82.28%

3.2 Future

ADXN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.71% yearly.
ADXN is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y103.68%
EPS Next 2Y24.85%
EPS Next 3Y19.49%
EPS Next 5Y14.71%
Revenue Next Year-73.55%
Revenue Next 2Y-54.41%
Revenue Next 3Y-40.77%
Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ADXN Yearly Revenue VS EstimatesADXN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2M 4M 6M
ADXN Yearly EPS VS EstimatesADXN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -10 -20 -30 -40 -50

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 1.43 indicates a rather cheap valuation of ADXN.
ADXN's Price/Earnings ratio is rather cheap when compared to the industry. ADXN is cheaper than 99.64% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 29.63, ADXN is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for ADXN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 1.43
Fwd PE N/A
ADXN Price Earnings VS Forward Price EarningsADXN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADXN Per share dataADXN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

ADXN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ADXN's earnings are expected to grow with 19.49% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y24.85%
EPS Next 3Y19.49%

More info and screens

0

5. Dividend

5.1 Amount

ADXN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADDEX THERAPEUTICS LTD

NASDAQ:ADXN (2/21/2025, 8:00:05 PM)

7.52

-0.28 (-3.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-22 2024-11-22/bmo
Earnings (Next)03-24 2025-03-24/amc
Inst Owners4.05%
Inst Owner Change-92.29%
Ins Owners10.84%
Ins Owner ChangeN/A
Market Cap8.04M
Analysts38
Price Target8.81 (17.15%)
Short Float %0.4%
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.72%
PT rev (3m)-18.03%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)107.04%
EPS NY rev (3m)107.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)133.37%
Revenue NY rev (3m)-20.46%
Valuation
Industry RankSector Rank
PE 1.43
Fwd PE N/A
P/S 12.21
P/FCF N/A
P/OCF N/A
P/B 0.65
P/tB 0.66
EV/EBITDA N/A
EPS(TTM)5.25
EY69.81%
EPS(NY)-6.25
Fwd EYN/A
FCF(TTM)-6.21
FCFYN/A
OCF(TTM)-6.21
OCFYN/A
SpS0.62
BVpS11.5
TBVpS11.47
PEG (NY)0.01
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 44.42%
ROE 48.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 912.38%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.78%
Cap/Sales 0.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.59
Quick Ratio 4.59
Altman-Z -34.09
F-Score6
WACC4.96%
ROIC/WACCN/A
Cap/Depr(3y)3.83%
Cap/Depr(5y)7.14%
Cap/Sales(3y)0.49%
Cap/Sales(5y)0.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)119.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.12%
EPS Next Y103.68%
EPS Next 2Y24.85%
EPS Next 3Y19.49%
EPS Next 5Y14.71%
Revenue 1Y (TTM)-76.09%
Revenue growth 3Y-24.84%
Revenue growth 5Y-24.47%
Sales Q2Q%-82.28%
Revenue Next Year-73.55%
Revenue Next 2Y-54.41%
Revenue Next 3Y-40.77%
Revenue Next 5Y-14.87%
EBIT growth 1Y65.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year50.22%
EBIT Next 3Y9.49%
EBIT Next 5Y11.55%
FCF growth 1Y63.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.38%
OCF growth 3YN/A
OCF growth 5YN/A